16956354

Source:http://linkedlifedata.com/resource/pubmed/id/16956354

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0332120, umls-concept:C0729866, umls-concept:C1457887, umls-concept:C1522326, umls-concept:C1524063, umls-concept:C1704272, umls-concept:C1709630, umls-concept:C2923059
pubmed:issue	6
pubmed:dateCreated	2006-11-27
pubmed:abstractText	To evaluate the potential of sildenafil, vardenafil and tadalafil, all phosphodiesterase-5 (PDE-5) inhibitors used for treating erectile dysfunction, for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/16956354-17125493
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100886721
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/3',5'-Cyclic-GMP Phosphodiesterases, http://linkedlifedata.com/resource/pubmed/chemical/Carbolines, http://linkedlifedata.com/resource/pubmed/chemical/Cyclic Nucleotide..., http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/PDE5A protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Pde5a protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Purines, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger, http://linkedlifedata.com/resource/pubmed/chemical/Sulfones, http://linkedlifedata.com/resource/pubmed/chemical/Triazines, http://linkedlifedata.com/resource/pubmed/chemical/sildenafil, http://linkedlifedata.com/resource/pubmed/chemical/tadalafil, http://linkedlifedata.com/resource/pubmed/chemical/vardenafil
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	1464-4096
pubmed:author	pubmed-author:HütterJoachimJ, pubmed-author:SandnerPeterP, pubmed-author:Stelte-LudwigBeatrixB, pubmed-author:TinelHannaH
pubmed:issnType	Print
pubmed:volume	98
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1259-63
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:16956354-3',5'-Cyclic-GMP Phosphodiesterases, pubmed-meshheading:16956354-Animals, pubmed-meshheading:16956354-Carbolines, pubmed-meshheading:16956354-Cyclic Nucleotide Phosphodiesterases, Type 5, pubmed-meshheading:16956354-Imidazoles, pubmed-meshheading:16956354-Male, pubmed-meshheading:16956354-Phosphodiesterase Inhibitors, pubmed-meshheading:16956354-Piperazines, pubmed-meshheading:16956354-Prostatic Hyperplasia, pubmed-meshheading:16956354-Prostatism, pubmed-meshheading:16956354-Purines, pubmed-meshheading:16956354-RNA, Messenger, pubmed-meshheading:16956354-Rats, pubmed-meshheading:16956354-Rats, Sprague-Dawley, pubmed-meshheading:16956354-Sulfones, pubmed-meshheading:16956354-Treatment Outcome, pubmed-meshheading:16956354-Triazines
pubmed:year	2006
pubmed:articleTitle	Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
pubmed:affiliation	Bayer Health Care AG-Institute for Product-Related Research, Wuppertal, Germany.
pubmed:publicationType	Journal Article